Akoya Biosciences Inc at JPMorgan Healthcare Conference Transcript
All right. Good morning, everyone. I'm Julia Qin, lead analyst covering life science tools and diagnostics at JPMorgan, and it's my great pleasure to introduce you to our next presentation this morning by Akoya. And with that, let me turn it over to Brian. Welcome.
All right. Well, thank you, Julia, and thank you to the team at JPMorgan for your continued support and the invitation. And it's great to be back in person in Sage feed and all. I appreciate everybody's time today.
Again, I'm Brian McKelligon, CEO of Akoya. I've been with the company since middle of 2017 is whopping employee #3 at the time, and I'm excited to share with you a little bit about our journey and where we stand today and how we think about our progress going forward into 2023 and beyond. But prior to that, our friends in legal would like me to give you the appropriate disclaimers. And I invite you to look at that at your convenience it is
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
